Scarica l'app Stockscreener
44.04
0.25%
-0.11
Dopo l'orario di chiusura:
44.13
0.09
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Exelixis Inc Borsa (EXEL) Ultime notizie
EXELIXIS Q4 2025 Earnings Preview: Recent $EXEL Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer - MSN
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story - Yahoo Finance
Assessing Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And STELLAR-316 Trial Plans - Yahoo Finance
EXELExelixis Announces Third Quarter 2009 Financial Results - ADVFN
EXEL: HC Wainwright Raises Price Target and Maintains Buy Rating - GuruFocus
How risky is Exelixis Inc. stock nowRate Cut & Smart Swing Trading Techniques - ulpravda.ru
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study - Finviz
EXEL Receives Downgrade from Morgan Stanley, Price Target Increa - GuruFocus
What is the fair value of Exelixis Inc. stock nowMarket Trend Report & Risk Controlled Daily Plans - ulpravda.ru
Is It Time To Reassess Exelixis (EXEL) After Strong Multi‑Year Share Price Gains - Yahoo Finance
What 10 Analyst Ratings Have To Say About Exelixis - Benzinga
Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48 - MarketScreener
2 Healthcare Stocks to Buy for 2026 and Beyond - Finviz
Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols - ADVFN
Exelixis stock rating downgraded by Morgan Stanley despite price target hike - Investing.com Canada
Exelixis and Natera to collaborate on MRD-guided cancer trial By Investing.com - Investing.com Nigeria
2 Healthcare Stocks to Buy for 2026 and Beyond - The Motley Fool
The Truth About Exelixis Inc: Is This Quiet Cancer Stock About To Explode? - AD HOC NEWS
Exelixis and Natera stocks rise on colorectal cancer trial collaboration By Investing.com - Investing.com South Africa
Exelixis and Natera stocks rise on colorectal cancer trial collaboration - Investing.com
Exelixis, Natera to Collaborate on Phase 3 Colorectal Cancer Trial - MarketScreener
Exelixis and Natera to collaborate on Stellar-316, a phase 3 pivotal trial of zanzalintinib - MarketScreener
Exelixis (EXEL) Collaborates on Innovative Colorectal Cancer Tri - GuruFocus
Exelixis and Natera to collaborate on MRD-guided cancer trial - Investing.com India
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer - Yahoo Finance
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 - The Joplin Globe
Dental EconomicsExelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 - FinancialContent
Exelixis cut to underperform at BofA on valuation and lack of catalysts - MSN
Exelixis (EXEL) Downgraded by Bank of America Amid Valuation Con - GuruFocus
Exelixis (EXEL) Downgraded by Bank of America Amid Valuation Concerns - GuruFocus
Exelixis Faces Limited High-Impact Catalysts, BofA Says - MarketScreener
BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43 - marketscreener.com
Exelixis, Inc. (EXEL): Investor Outlook on a Biotech Powerhouse with a 30.56% Return on Equity - DirectorsTalk Interviews
Gains Report: Can Exelixis Inc EX9 stock sustain margin levels2025 Trading Recap & Momentum Based Trading Ideas - moha.gov.vn
Aug Sectors: Is Exelixis Inc EX9 stock cheap vs fundamentalsEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, & Marketing to Support Commercialization of Cabozan... - ADVFN
See How Rare Bullish Inflows Lift Outliers Like Exelixis - Yahoo Finance
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Trading the Move, Not the Narrative: (EXEL) Edition - Stock Traders Daily
Does Exelixis (NASDAQ:EXEL) Deserve A Spot On Your Watchlist? - Yahoo Finance
Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma - ADVFN
Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib & Abiraterone in Men With Castr... - ADVFN
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafeni... - ADVFN
Exelixis Inc Stock Analysis and ForecastLarge Cap Stability Picks & Double Or Triple Capital - earlytimes.in
Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib & Atezolizumab in Metastatic C... - ADVFN
Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metasta... - ADVFN
Exelixis Receives $150 Million Funding Commitment From Deerfield Management - ADVFN
Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration - ADVFN
Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refract... - ADVFN
Exelixis Earnings Notes - Trefis
History Review: Is Exelixis Inc stock trading at a premium valuationPortfolio Return Summary & Free Expert Approved Momentum Trade Ideas - moha.gov.vn
Exelixis (MIC:EXEL-RM) EV-to-FCF : 0.00 (As of Dec. 26, 2025) - GuruFocus
Exelixis, Inc. (EXEL) Stock Analysis: Navigating the Biotech Frontier with a Strong R&D Pipeline and Robust Revenue Growth - DirectorsTalk Interviews
Exelixis (HAM:EX9) EV-to-OCF : 13.21 (As of Dec. 22, 2025) - GuruFocus
Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday - MSN
Published on: 2025-12-21 13:28:36 - Улправда
How Exelixis Inc. stock reacts to job market dataMarket Risk Report & Safe Swing Trade Setups - ulpravda.ru
Behavioral Patterns of EXEL and Institutional Flows - news.stocktradersdaily.com
Published on: 2025-12-20 10:46:18 - Улправда
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):